Abstract-Increases in arginase activity have been reported in a variety of disease conditions characterized by vascular dysfunction. Arginase competes with NO synthase for their common substrate arginine, suggesting a cause and effect relationship. We tested this concept by experiments with streptozotocin diabetic rats and high glucose (HG)-treated bovine coronary endothelial cells (BCECs). Our studies showed that diabetes-induced impairment of vasorelaxation to acetylcholine was correlated with increases in reactive oxygen species and arginase activity and arginase I expression in aorta and liver. Treatment of diabetic rats with simvastatin (5 mg/kg per day, subcutaneously) or L-citrulline (50 mg/kg per day, orally) blunted these effects. Acute treatment of diabetic coronary arteries with arginase inhibitors also reversed the impaired vasodilation to acetylcholine. Treatment of BCECs with HG (25 mmol/L, 24 hours) also increased arginase activity. This effect was blocked by treatment with simvastatin (0.1 mol/L), the Rho kinase inhibitor Y-27632 (10 mol/L), or L-citrulline (1 mmol/L). Superoxide and active RhoA levels also were elevated in HG-treated BCECs. Furthermore, HG significantly diminished NO production in BCECs. Transfection of BCECs with arginase I small interfering RNA prevented the rise in arginase activity in HG-treated cells and normalized NO production, suggesting a role for arginase I in reduced NO production with HG. These results indicate that increased arginase activity in diabetes contributes to vascular endothelial dysfunction by decreasing L-arginine availability to NO synthase. (Circ Res.
2008;102:95-102.)Key Words: arginine Ⅲ coronary arteries Ⅲ diabetes Ⅲ endothelial nitric oxide synthase Ⅲ oxidative stress Ⅲ vascular endothelial function Ⅲ vasodilation V ascular dysfunction is a major cause of morbidity and mortality in diabetic patients. 1 The pathological process is characterized by impaired endothelial cell production of the vasodilator and antiplatelet adhesion factor NO and/or decreased NO bioavailability. NO is a major regulator of vascular tone and integrity. In endothelial cells, NO is produced by activity of endothelial NO synthase (eNOS) on its substrate L-arginine. Reduced availability of L-arginine to eNOS has been implicated in vascular dysfunction in diabetes and a variety of other disease conditions. Arginase, which metabolizes L-arginine to urea and ornithine, competes directly with NOS for L-arginine. Hence increases in arginase activity can decrease tissue and cellular arginine levels, reducing its availability to eNOS. 2 This may lead to decreased NO production and increased production of superoxide by eNOS. 3 Enhanced arginase activity has been implicated in a number of conditions characterized by vascular dysfunction, including diabetic erectile dysfunction, pulmonary hypertension, ischemia/reperfusion, atherosclerosis, and agingassociated endothelial dysfunction. 4 -9 During diabetes, impaired vascular function is closely associated with oxidative stress and v...